192 related articles for article (PubMed ID: 27863212)
1. Antiangiogenic Therapeutic Potential of Peptides Derived from the Molecular Motor KIF13B that Transports VEGFR2 to Plasmalemma in Endothelial Cells.
Yamada KH; Kang H; Malik AB
Am J Pathol; 2017 Jan; 187(1):214-224. PubMed ID: 27863212
[TBL] [Abstract][Full Text] [Related]
2. KIF13B-mediated VEGFR2 trafficking is essential for vascular leakage and metastasis in vivo.
Waters SB; Dominguez JR; Cho HD; Sarich NA; Malik AB; Yamada KH
Life Sci Alliance; 2022 Jan; 5(1):. PubMed ID: 34670814
[TBL] [Abstract][Full Text] [Related]
3. KIF13B regulates angiogenesis through Golgi to plasma membrane trafficking of VEGFR2.
Yamada KH; Nakajima Y; Geyer M; Wary KK; Ushio-Fukai M; Komarova Y; Malik AB
J Cell Sci; 2014 Oct; 127(Pt 20):4518-30. PubMed ID: 25128562
[TBL] [Abstract][Full Text] [Related]
4. VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
Waters SB; Zhou C; Nguyen T; Zelkha R; Lee H; Kazlauskas A; Rosenblatt MI; Malik AB; Yamada KH
Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):5. PubMed ID: 33533881
[TBL] [Abstract][Full Text] [Related]
5. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis.
Lin YC; Chao TY; Yeh CT; Roffler SR; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):144-155. PubMed ID: 27834687
[TBL] [Abstract][Full Text] [Related]
6. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
8. Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis.
Chiodelli P; Rezzola S; Urbinati C; Federici Signori F; Monti E; Ronca R; Presta M; Rusnati M
Oncogene; 2017 Nov; 36(47):6531-6541. PubMed ID: 28783175
[TBL] [Abstract][Full Text] [Related]
9. KIF13B mediates VEGFR2 recycling to modulate vascular permeability.
Cho HD; Nhàn NTT; Zhou C; Tu K; Nguyen T; Sarich NA; Yamada KH
Cell Mol Life Sci; 2023 Mar; 80(4):91. PubMed ID: 36928770
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
13. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
14. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
Budd S; Byfield G; Martiniuk D; Geisen P; Hartnett ME
Exp Eye Res; 2009 Nov; 89(5):718-27. PubMed ID: 19576214
[TBL] [Abstract][Full Text] [Related]
15. Total saponins from Albizia julibrissin inhibit vascular endothelial growth factor-mediated angiogenesis in vitro and in vivo.
Cai W; Li Y; Yi Q; Xie F; Du B; Feng L; Qiu L
Mol Med Rep; 2015 May; 11(5):3405-13. PubMed ID: 25607254
[TBL] [Abstract][Full Text] [Related]
16. Genetic reduction of vascular endothelial growth factor receptor 2 rescues aberrant angiogenesis caused by epsin deficiency.
Tessneer KL; Pasula S; Cai X; Dong Y; McManus J; Liu X; Yu L; Hahn S; Chang B; Chen Y; Griffin C; Xia L; Adams RH; Chen H
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):331-337. PubMed ID: 24311377
[TBL] [Abstract][Full Text] [Related]
17. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
Cho HD; Lee KW; Won YS; Kim JH; Seo KI
J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
[TBL] [Abstract][Full Text] [Related]
18. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
19. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
20. Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
Yu Y; Yu J; Pei CG; Li YY; Tu P; Gao GP; Shao Y
Int J Clin Exp Pathol; 2015; 8(9):10355-64. PubMed ID: 26617743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
